Importantly, several ANG2 specific antibodies such as nesvacumab (REGN910) and MEDI3617 have been developed and are currently being tested in combination with other targeted therapies in clinical trials for cancer patients, including those focused on antiangiogenic combination with VEGF inhibitors (Table 1). The gene discussed is ANGPT2; the disease is cancer.